Treatment discontinuation · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful discontinuation of BZDs‐ post treatment Objective and subjective · patients with BZD harmful use, abuse or dependence
CBT (plus taper) probably leads to higher successful discontinuation of BZDs‐ post treatment Objective and… compared with taper (moderate certainty).
1 finding from 1 review
Successful discontinuation of BZDs‐ 12 month · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in successful discontinuation of BZDs‐ 12 month compared with taper (moderate certainty).
1 finding from 1 review
Successful discontinuation of BZDs‐ post treatment Objective and subjective · patients with BZD harmful use, abuse or dependence
It is very uncertain whether MI changes successful discontinuation of BZDs‐ post treatment Objective and… compared with TAU (very low certainty).
2 findings from 1 review
Intervention not reported
Continuation (12 months) · women aged ≤ 25 years with desire for contraception
It is very uncertain whether the intervention changes continuation (12 months) (very low certainty).
1 finding from 1 review
OR 1.48 [0.76, 2.89]
193 participants
Very low
Intervention not reported
Continuation (1 month; 6 months) · women aged ≤ 25 years with desire for contraception
The intervention showed no clear difference in continuation (1 month; 6 months) (moderate certainty).
1 finding from 1 review
OR 2.44 [0.19, 31.53]
23 participants
Moderate
Intervention not reported
Continuation (cycles 1 to 3; cycles 4 to 6) · women aged ≤ 25 years with desire for contraception
The intervention showed no clear difference in continuation (cycles 1 to 3; cycles 4 to 6) (moderate certainty).
1 finding from 1 review
OR 1.09 [0.49, 2.42]
130 participants
Moderate
Intervention not reported
Continuation (6 months) · women aged ≤ 25 years with desire for contraception
The intervention showed no clear difference in continuation (6 months) (moderate certainty).
1 finding from 1 review
OR 0.38 [0.05, 2.77]
20 participants
Moderate
Intervention not reported
Discontinuation: other personal reasons (12 months) · women aged ≤ 25 years with desire for contraception
It is very uncertain whether the intervention changes discontinuation: other personal reasons (12 months) (very low certainty).
1 finding from 1 review
OR 0.27 [0.09, 0.85]
193 participants
Very low
Intervention not reported
Discontinuation: pain, hormonal, bleeding, spotting, other medical, or planning pregnancy (12 months) · women aged ≤ 25 years with desire for contraception
1 finding from 1 review
no estimate extracted
193 participants
Very low
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (leading to discontinuation) · participants with recurrent herpes labialis
Topical foscarnet showed no clear difference in adverse effects during use of the preventative intervention (leading… compared with placebo (moderate certainty).
1 finding from 1 review
Continuation of breastfeeding · Breastfeeding women with breast abscesses
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).
1 finding from 1 review
Global: Discontinuation of Vitamin B6 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Discontinuation of Vitamin B6 compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation due to adverse events · Patients with fibromyalgia
It is very uncertain whether the intervention changes discontinuation due to adverse events (very low certainty).
1 finding from 1 review